XML 100 R32.htm IDEA: XBRL DOCUMENT

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	22. Subsequent Events Refer to Note 6. Investments for details related to the FDA approval received for MediBeacon's TGFR subsequent to year end. Refer to Note 11. Debt Obligations for details related to amendments to the Company's debt instruments subsequent to year end. Refer to Note 16. Equity and Temporary Equity for details related to R2 Technologies' issuance of a convertible note subsequent to year end.